A number of other equities analysts have also issued reports on the stock. Citigroup boosted their target price on shares of ProQR Therapeutics from $34.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, October 10th. Zacks Investment Research raised shares of ProQR Therapeutics from a “hold” rating to a “strong-buy” rating and set a $10.00 price target for the company in a report on Wednesday, August 14th. ValuEngine upgraded shares of ProQR Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, November 28th. Finally, Chardan Capital restated a “buy” rating and set a $25.00 price objective on shares of ProQR Therapeutics in a report on Friday, October 11th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $27.00.
Shares of PRQR traded down $0.09 during mid-day trading on Wednesday, hitting $9.63. The company’s stock had a trading volume of 2,304 shares, compared to its average volume of 349,853. The stock’s 50-day moving average is $7.75 and its two-hundred day moving average is $8.32. The firm has a market capitalization of $432.95 million, a PE ratio of -7.40 and a beta of 0.29. The company has a debt-to-equity ratio of 0.18, a quick ratio of 7.01 and a current ratio of 7.01. ProQR Therapeutics has a one year low of $5.49 and a one year high of $18.94.
About ProQR Therapeutics
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.
Featured Article: How can you know how many shares are floating?
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.